Link to Full Article ARESTAT™ formulated product progressing into clinical trial Cambridge, UK., 17th December 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, […]

Link to Full Article Development of a rapid acting concentrated insulin for advanced delivery systems and enabling fewer injections for high dose diabetics Cambridge, UK., 14 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives announces dosing of the first patient in a Phase I clinical […]

Link to Full Article AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®   Cambridge, UK., 15 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, presented positive results for the Phase I clinical trial of its ultra-rapid acting […]

Link to Full Article Arecor innovative product formulations applied to oncology and rare orphan diseases Cambridge, UK, 19 March 2020: Arecor Limited (“Arecor” or “the Company”), the  biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has extended its multi-product collaboration with a US-based clinical stage biotechnology company. Under the collaboration, Arecor […]

Link to Full Article Pharma partner has an exclusive option to a global, royalty bearing licence Cambridge, UK., 13 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with a top five pharmaceutical company. The pharmaceutical […]